SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates2/2/2006 10:43:52 AM
Read Replies (1) of 4974
 
Pump...

Message 22109296

...and dump ...

Hollis-Eden Pharmaceuticals to Raise $26.0 Million Through Sale of Common Stock and Warrants

SAN DIEGO--(BUSINESS WIRE)--Feb. 2, 2006--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) today announced that it has entered into definitive agreements to raise $26.0 million in gross proceeds through the sale of shares of its common stock and warrants to new and existing institutional investors pursuant to the Company's existing shelf registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). The Company has entered into purchase agreements with these investors pursuant to which the Company has agreed to sell a total of 4,000,000 shares of its common stock at $6.50 per share and to issue these investors four-year warrants to purchase up to an additional 800,000 shares of the Company's common stock at an exercise price of $8.75 per share. The warrants are not exercisable until six months following issuance. The closing of the transaction is expected to occur on or about February 6, 2006. Rodman & Renshaw, LLC acted as exclusive lead placement agent for the offering. Canaccord Adams, Inc acted as exclusive co-placement agent for the offering...

(edit)
finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext